Kyle B. Brothers, MD, PhD and Esther E. Knapp, MD, MBE
Direct-to-consumer genetic testing requires that physicians share decision making with patients, not order unnecessary tests or interventions, and refer to genetic specialists when necessary.
AMA J Ethics. 2018;20(9):E812-818. doi:
10.1001/amajethics.2018.812.
Clara C. Hildebrandt, MD and Jonathan M. Marron, MD, MPH
Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.
AMA J Ethics. 2018;20(9):E826-833. doi:
10.1001/amajethics.2018.826.
Using data from comparative effectiveness studies to inform cost-effectiveness analyses or other economic evaluations would strengthen ethical policy making.
AMA J Ethics. 2015;17(7):651-655. doi:
10.1001/journalofethics.2015.17.7.pfor1-1507.
Dr Rajesh R. Tampi joins Ethics Talk to discuss his article, coauthored with Drs Aarti Gupta and Iqbal Ahmed: “Why Does the US Overly Rely on International Medical Graduates in Its Geriatric Psychiatric Workforce?”
Developing technologies for personalized medicine may be misused to popularize the idea that one can infer a person’s genetic makeup from observer-defined or self-reported assignment to a race or ethnic group.
Jodi Halpern, MD, PhD and Richard L. Kravitz, MD, MSPH
Just as people frequently support political parties without endorsing their entire platforms, perhaps physicians can support a health care advocacy organization without agreeing with its screening guidelines.
This month, AMA Journal of Ethics theme editor Jacquelyn Nestor, a fifth-year MD/PhD student at Hofstra-Northwell School of Medicine, interviewed Allen Buchanan, PhD, about how we can safely explore cutting-edge biomedical enhancements.